KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares Issued
Ratios

Jazz Pharmaceuticals (JAZZ) Short-Term Debt repayments: 2015-2017

Historic Short-Term Debt repayments for Jazz Pharmaceuticals (JAZZ) over the last 1 years, with Sep 2017 value amounting to $500.0 million.

  • Jazz Pharmaceuticals' Short-Term Debt repayments was N/A to $500.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $1.0 billion, marking a year-over-year change of. This contributed to the annual value of $500.0 million for FY2020, which is N/A change from last year.
  • Jazz Pharmaceuticals' Short-Term Debt repayments amounted to $500.0 million in Q3 2017, which was up 150.00% from $200.0 million recorded in Q2 2017.
  • Jazz Pharmaceuticals' Short-Term Debt repayments' 5-year high stood at $500.0 million during Q3 2017, with a 5-year trough of $80.0 million in Q4 2015.
  • Its 3-year average for Short-Term Debt repayments is $216.0 million, with a median of $150.0 million in 2017.
  • Data for Jazz Pharmaceuticals' Short-Term Debt repayments shows a peak YoY spiked of 87.50% (in 2016) over the last 5 years.
  • Quarterly analysis of 3 years shows Jazz Pharmaceuticals' Short-Term Debt repayments stood at $80.0 million in 2015, then surged by 87.50% to $150.0 million in 2016, then reached $500.0 million in 2017.
  • Its Short-Term Debt repayments was $500.0 million in Q3 2017, compared to $200.0 million in Q2 2017 and $150.0 million in Q1 2017.